New asthma drugs small molecule inhaled corticosteroids

Airway remodeling is when there are permanent physical changes to the airways that also affects how they work. This may happen after chronic long-term asthma. After cycles of inflammation, damage and repair to the airways. permanent remodeling of the airways may occur. This is when the physical structure of the airway changes. This will cause permanent airway narrowing (they are always more narrow than normal and get narrower during an asthma attack), bronchospasms are more easily triggered (bronchial hyperresponsivenes), airway edema (fluid in the airway), and mucus hypersecretion (too much mucous is made) as well as the build-up of collagen around the airway which is called fibrosis. Airway remodeling has been observed in chldren as young as six. [28]

Patient education: Asthma treatment in adolescents and adults (Beyond the Basics)
Patient education: How to use a peak flow meter (Beyond the Basics)
Patient education: Asthma inhaler techniques in adults (Beyond the Basics)
Patient education: Trigger avoidance in asthma (Beyond the Basics)
Patient education: Preeclampsia (Beyond the Basics)
Patient education: Preterm labor (Beyond the Basics)
Patient education: C-section (cesarean delivery) (Beyond the Basics)
Patient education: Influenza symptoms and treatment (Beyond the Basics)
Patient education: Deciding to breastfeed (Beyond the Basics)

Cinqair
In March, 2016, Teva Pharmaceuticals' Cinqair (reslizumab) was approved as an add-on maintenance treatment of severe asthma in adults not well-controlled on their current asthma medications. Cinqair reduces eosinophils, a type of white blood cell that contributes to asthma development. It is classified as an interleukin 5 antagonist monoclonal antibody (IgG4 kappa). Cinqair is given once every four weeks by injection in your doctor's office. Common side effects included anaphylaxis, cancer, and muscle pain. Nucala
Nucala (mepolizumab) is GlaxoSmithkline's IL-5 antagonist FDA-approved in November 2015 for the add-on maintenance treatment of severe eosinophilic asthma. Nucala blocks interleukin-5 and reduces inflammatory-producing white blood cell accumulation in the lungs. Like Cinqair, Nucala is given by injection every 4 weeks. Common side effects may include headache, injection site reactions, back pain, and weakness.

New asthma drugs small molecule inhaled corticosteroids

new asthma drugs small molecule inhaled corticosteroids

Media:

new asthma drugs small molecule inhaled corticosteroidsnew asthma drugs small molecule inhaled corticosteroidsnew asthma drugs small molecule inhaled corticosteroidsnew asthma drugs small molecule inhaled corticosteroidsnew asthma drugs small molecule inhaled corticosteroids

http://buy-steroids.org